Financial Performance - The company's operating revenue for Q1 2024 was ¥675,882,973.16, representing a 4.01% increase compared to ¥649,826,753.50 in the same period last year[40]. - The net profit attributable to shareholders of the listed company decreased by 89.58% to ¥16,924,936.43 from ¥162,393,315.01 year-on-year[40]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,084,077.60, down 73.28% from ¥71,427,627.21 in the previous year[40]. - The basic and diluted earnings per share both dropped to ¥0.11, a decline of 89.91% from ¥1.09 in the same period last year[40]. - The total comprehensive income attributable to the parent company's shareholders was significantly impacted, with a net profit of ¥16,924,936.43 compared to ¥162,393,315.01 previously, a decrease of approximately 89.6%[50]. - The operating profit for the current period was ¥41,355,597.39, down from ¥191,474,382.80, reflecting a decline of about 78.4%[50]. Cash Flow and Investments - The net cash flow from investment activities for the first quarter of 2024 was -¥196,363,723.78, a 63.02% increase in outflow compared to the same period last year[5]. - The net cash flow from operating activities was ¥125,706,825.28, an increase of 4.37% compared to ¥120,447,583.12 in the same period last year[40]. - Cash inflow from operating activities totaled ¥679,993,838.41, up from ¥618,035,398.46, reflecting an increase of around 10.0%[67]. - Cash outflow from operating activities was ¥554,287,013.13, compared to ¥497,587,815.34, which is an increase of about 11.4%[67]. - The company reported a significant decrease in investment income, down 99.37% to ¥583,182.02, due to revaluation of equity in a previously acquired hospital[5]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,739,576,891.70, a decrease of 1.57% from ¥4,815,000,387.93 at the end of the previous year[40]. - The total liabilities decreased from ¥2,496,787,457.87 to ¥2,432,122,786.09, a reduction of approximately 2.6%[49]. - The total equity attributable to shareholders decreased from ¥2,291,622,601.45 to ¥2,278,746,073.33, a decrease of approximately 0.6%[49]. - Current liabilities decreased to ¥774,628,304.72 from ¥1,043,136,742.01, a reduction of approximately 25.7%[62]. - Non-current assets totaled ¥3,564,118,373.11, down from ¥3,600,194,099.58, indicating a decrease of about 1.0%[62]. Borrowings and Financial Expenses - The company's short-term borrowings decreased by 57.77% to ¥98,428,416.67, resulting from repayments made during the period[5]. - The company's long-term borrowings increased by 206.71% to ¥290,778,074.66, reflecting new loans taken from banks during the period[5]. - Financial expenses increased by 40.33% to ¥18,121,370.70, mainly due to higher interest expenses from leasing new hospital properties[5]. Other Financial Metrics - The company's prepaid expenses increased by 203.24% to ¥29,497,219.69, primarily due to increased procurement payments for newly opened hospitals[5]. - The company's contract liabilities rose by 30.68% to ¥20,706,725.05, driven by growth in optical business and increased prepayments for eyewear[5]. - The company experienced a 104.89% increase in taxes and surcharges, totaling ¥1,261,475.64, mainly due to property tax and stamp duty from new properties[5]. - The company recorded a government subsidy of ¥1,027,746.09 during the reporting period[55]. - The weighted average return on net assets was 0.74%, a decrease of 6.82% from 7.56% in the same period last year[40]. - The company has maintained its capital reserve at approximately ¥1,735,326,760.56, showing stability in this area[49]. Share Repurchase - The company continued its stock repurchase program, resulting in a 99.40% increase in treasury shares to ¥59,770,175.60[5]. - The company repurchased a total of 755,267 shares, accounting for 0.50% of the total share capital, with a total transaction amount of ¥59,770,175.60[47].
普瑞眼科(301239) - 2024 Q1 - 季度财报